DUBLIN--(BUSINESS WIRE)--The "Stereotactic Surgery Devices Market Size, Share & Trends Analysis Report By Type (Gamma Knife, Linear Accelerator, CyberKnife, Proton Beam Therapy), By Region, And Segment Forecasts, 2018 - 2025" report has been added to ResearchAndMarkets.com's offering.
The global stereotactic surgery devices market size is expected to reach USD 25.9 billion by 2025, expanding at a CAGR of 6.1% during the forecast period.
Stereotactic surgery is a minimally invasive alternative for traditional invasive ablation and biopsy methods. Since, stereotactic surgery has various advantages such as higher efficacy, minimal or no surgical incisions, and lower risk of damage to healthy cells, it is replacing conventional radiotherapies. These surgical procedures have helped overcome drawbacks associated with traditional invasive surgeries, such as destruction of healthy cells and higher risk of recurrence & postoperative complications.
Only around 10.0% of the population in low and middle-income countries have access to radiation therapy, owing to dearth of radiation therapy devices. A market leader, Elekta, in its 2016 annual report stated that the number of installations of linear accelerators in high-income countries was approximately 13,000, whereas the requirement was around 25,000. Hence, huge demand-supply discrepancy of radiotherapy devices is likely to open new avenues for major market players in developing countries.
Some of the major players operating in the market are Siemens Ag, Elekta AB, Varian Medical Systems, IBA, and Accuray Incorporated
Key Topics Covered:
Chapter 1 Report Scope
Chapter 2 Research Methodology
Chapter 3 Objective
Chapter 4 Executive Summary
Chapter 5 Market Definitions
Chapter 6 Industry Outlook
Chapter 7 Stereotactic Surgery Devices Market: Product Estimates & Trend Analysis
Chapter 8 Stereotactic Surgery Devices Market: Regional Estimates & Trend Analysis, by Product Type
Chapter 9 Competitive Landscape
- AstraZeneca
- Bayer AG
- Merck KGaA
- Abbott
- Pfizer, Inc.
- Sanofi
- Bristol Myers Squibb Company
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Ferring B.V.
For more information about this report visit https://www.researchandmarkets.com/research/c2vj9f/global?w=4
